Evidence map›Paper›PMID 33429174›Full record

Trial reportAmerican journal of otolaryngology

Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: A randomized controlled trial.

Abdelrahman Ahmed Abdelalim, Ayman Abdelaal Mohamady, Rasha Abdelhamid Elsayed, Mona Ahmed Elawady, Abdelhakim Fouad Ghallab

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of otolaryngology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04484493 (Role of Corticosteroid Nasal Spray in Recovery of Smell Sensation in COVID-19 Patients), which is not on this map. Cited by 86 papers, 17 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 17 pooled it
16.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04484493 phase3completednot on this map

Role of Corticosteroid Nasal Spray in Recovery of Smell Sensation in COVID-19 Patients

TypeinterventionalSponsorBenha UniversityRan2020 to 2020Enrolled100ConditionsCovid19, AnosmiaArmsmometasone furoate nasal spray
3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 17 syntheses or guidelines pooled it, 147 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Inhaled corticosteroids' effect on COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials.Canadian journal of respiratory therapy : CJRT = Revue canadienne de la therapie respiratoire : RCTR · 2023
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. ESCMID rapid guidelines for assessment and management of long COVID.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022
    Guideline
  11. Efficacy of topical steroids for the treatment of olfactory disorders caused by COVID-19: A systematic review and meta-analysis.Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery · 2022
    Pooled it
  12. Systemic corticosteroids for the treatment of COVID-19.The Cochrane database of systematic reviews · 2021
    Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Trial
  19. Trial
  20. Trial

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Abdelrahman Ahmed AbdelalimDepartment of Otorhinolaryngology, Benha Faculty of Medicine, Benha University, Egypt. Electronic address: abdelrahman.ahmed@fmed.bu.edu.eg.
Ayman Abdelaal MohamadyDepartment of Otorhinolaryngology, Benha Faculty of Medicine, Benha University, Egypt.
Rasha Abdelhamid ElsayedDepartment of Medical Microbiology and Immunology, Benha Faculty of Medicine, Benha University, Egypt.
Mona Ahmed ElawadyDepartment of Public Health, Benha Faculty of Medicine, Benha University, Egypt.
Abdelhakim Fouad GhallabDepartment of Otorhinolaryngology, Benha Faculty of Medicine, Benha University, Egypt.
Benha University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate the role of the topical corticosteroid, mometasone furoate, nasal spray in the treatment of post COVID-19 anosmia.

methodsA prospective, randomized, controlled trial was conducted among patients with post COVID-19 anosmia. One hundred patients were randomly assigned to two groups; group I included 50 patients received mometasone furoate nasal spray in an appropriate dose of 2 puff (100 μg) once daily in each nostril for 3 weeks with olfactory training, group II included 50 patients were advised to keep on olfactory training only. The assessment of smell was done using (Visual Analog Scale from 0 to 10). All patients were initially evaluated after their recovery from COVID-19 and followed up for 3 weeks. The smell scores were recorded weekly and the duration of smell loss was recorded from the onset of anosmia till the full recovery.

resultsIn both groups, the smell scores significantly improved by the end of the third week (P < 0.001). By comparing smell scores between both groups after 1 week, 2 weeks, and 3 weeks of treatment, there were no statistically significant differences between both groups. In group I, (62%) of patients completely recovered their sense of smell after 3 weeks of treatment, compared to (52%) of patients in group II (P = 0.31).

conclusionThe results suggested that using mometasone furoate nasal spray as a topical corticosteroid in the treatment of post COVID-19 anosmia offers no superiority benefits over the olfactory training, regarding smell scores, duration of anosmia, and recovery rates.

trial registrationClinicalTrials.gov ID: NCT04484493.

Indexed as

Nasal SpraysAdolescentAdultAge FactorsAnosmiaAnti-Inflammatory AgentsCOVID-19Diabetes ComplicationsFemaleHumansMaleMiddle AgedMometasone FuroateProspective StudiesRecovery of FunctionVisual Analog ScaleAnti-Inflammatory AgentsMometasone FuroateNasal SpraysAnosmiaCOVID-19Mometasone furoateNasal spraySmell

Identifiers

PMID33429174
PMCPMC7836546
OpenAlexW3118739000

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.